Autopsy report · NCT00390364

Everolimus in Treating Patients With Advanced or Metastatic Colorectal Cancer That Did Not Respond to Previous Therapy

“Withdrawn due to low accrual”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 1 year before it stopped.
• 1 participant enrolled.
• Results were posted on the registry 7 years after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Sponsor type

University, hospital or other

Conditions

Colorectal Cancer

Interventions

everolimus; antiangiogenesis therapy; biopsy; diagnostic procedure; gene expression analysis; immunohistochemistry staining method

Participants

1

Sites

1

Countries

United States

Trials that died the same way

• Fenretinide Followed by Surgery Compared With Surgery Alone in Preventing Ovarian Cancer in Patients at Increased Risk
  “Withdrawn due to poor accrual” (97% match in meaning)
• Selective Serotonin Reuptake Inhibitors (SSRIs) in Borderline Personality Disorder
  “Funding withdrawn due to inability to accrue” (76% match in meaning)
• A Study to Assess the Effects of MK0822 in Reducing the Risk of Bone Metastasis in Women With Breast Cancer (0822-029)
  “Withdrawn for administrative reasons” (76% match in meaning)
• The Effects of Sapropterin Dihydrochloride Supplementation on in Vivo Redox Status in Patients With Classical PKU
  “Withdrawn due to no funding” (75% match in meaning)
• The Effect of Light Therapy on Post-Surgical Pain
  “Withdrawn due to lack of resources” (75% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.